Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Zhiwei He

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1434-2170; OpenAlex author ID A5022984632. Sources: OpenAlex.

Their work

Papers
35 (first author 9, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
53
Papers, trials and grants by year

2019: 3 papers · 2020: 4 papers · 2021: 10 papers · 2022: 6 papers · 2023: 4 papers · 2024: 1 paper · 2025: 6 papers · 2026: 1 paper

Papers 35

  1. Targeting PSMD14 increases chemotherapeutic sensitivity to gemcitabine by inhibiting the WNT/β-catenin pathway and glycolysis in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08958-w↗
  2. TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4. Co-author DOI 10.1016/j.drup.2024.101171↗
  3. CDCA7 enhances STAT3 transcriptional activity to regulate aerobic glycolysis and promote pancreatic cancer progression and gemcitabine resistance. Co-author DOI 10.1038/s41419-025-07399-1↗
  4. ENO1-mediated deoxycytidine synthesis and gemcitabine resistance by stabilizing RRM2 in pancreatic cancer. Co-author DOI 10.1038/s41419-025-08061-6↗
  5. Sciellin inhibits senescence and promotes pancreatic cancer progress by activating the notch signaling pathway. Co-author DOI 10.1038/s41598-025-88265-0↗
  6. Senescence-related circRNA circHIF-1α is associated with pancreatic cancer progression. Co-author DOI 10.1186/s12935-025-03645-w↗
  7. INHBA promotes chemoresistance in pancreatic cancer by enhancing CTPS1 stability and mediating pyrimidine metabolism. Co-author DOI 10.1186/s12935-025-03984-8↗
  8. TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway. First author DOI 10.1038/s41419-024-07324-y↗
  9. FOXQ1 promotes pancreatic cancer cell proliferation, tumor stemness, invasion and metastasis through regulation of LDHA-mediated aerobic glycolysis. Co-author DOI 10.1038/s41419-023-06207-y↗
  10. FBXO28 promotes proliferation, invasion, and metastasis of pancreatic cancer cells through regulation of SMARCC2 ubiquitination. Co-author DOI 10.18632/aging.204780↗
  11. Correction for: FBXO28 promotes proliferation, invasion, and metastasis of pancreatic cancer cells through regulation of SMARCC2 ubiquitination. Co-author DOI 10.18632/aging.205071↗
  12. Identification of gene signatures related to hypoxia and angiogenesis in pancreatic cancer to aid immunotherapy and prognosis. Co-author DOI 10.3389/fonc.2023.1119763↗
  13. Hypoxia-induced long noncoding RNA NR2F1-AS1 maintains pancreatic cancer proliferation, migration, and invasion by activating the NR2F1/AKT/mTOR axis. Co-author DOI 10.1038/s41419-022-04669-0↗
  14. Autophagy-associated circRNA circATG7 facilitates autophagy and promotes pancreatic cancer progression. Co-author DOI 10.1038/s41419-022-04677-0↗
  15. LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2. First author DOI 10.1038/s41419-022-05172-2↗
  16. FOXD1 facilitates pancreatic cancer cell proliferation, invasion, and metastasis by regulating GLUT1-mediated aerobic glycolysis. Co-author DOI 10.1038/s41419-022-05213-w↗
  17. RHBDL2 promotes the proliferation, migration, and invasion of pancreatic cancer by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling path… Co-author DOI 10.1038/s41419-022-05379-3↗
  18. MICAL1 facilitates pancreatic cancer proliferation, migration, and invasion by activating WNT/β-catenin pathway. Co-author DOI 10.1186/s12967-022-03749-1↗
  19. YEATS2 is a target of HIF1α and promotes pancreatic cancer cell proliferation and migration. Co-author DOI 10.1002/jcp.29995↗
  20. Long noncoding RNA LINC00941 promotes pancreatic cancer progression by competitively binding miR-335-5p to regulate ROCK1-mediated LIMK1/Cofilin-1 signaling. First author DOI 10.1038/s41419-020-03316-w↗
  21. LncRNA CERS6-AS1 promotes proliferation and metastasis through the upregulation of YWHAG and activation of ERK signaling in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03921-3↗
  22. [6]-Paradol suppresses proliferation and metastases of pancreatic cancer by decreasing EGFR and inactivating PI3K/AKT signaling. Co-author DOI 10.1186/s12935-021-02118-0↗
  23. Hypoxic pancreatic stellate cell-derived exosomal mirnas promote proliferation and invasion of pancreatic cancer through the PTEN/AKT pathway. Co-author DOI 10.18632/aging.202569↗
  24. Hypoxia-related gene FUT11 promoted pancreatic cancer progression via maintaining the stabilization of PDK1 Co-author DOI 10.21203/rs.3.rs-152464/v3↗
  25. Hypoxia-Related Gene FUT11 Promoted Pancreatic Cancer Progression Via Maintaining The Stabilization of PDK1 Co-author DOI 10.21203/rs.3.rs-153965/v1↗
  26. Hypoxia-Induced ZWINT Mediates Pancreatic Cancer Proliferation by Interacting With p53/p21. First author DOI 10.3389/fcell.2021.682131↗
  27. MiR-489-3p Reduced Pancreatic Cancer Proliferation and Metastasis By Targeting PKM2 and LDHA Involving Glycolysis. First author DOI 10.3389/fonc.2021.651535↗
  28. miRNA‑7515 suppresses pancreatic cancer cell proliferation, migration and invasion via downregulating IGF‑1 expression. Co-author DOI 10.3892/or.2021.8151↗
  29. LncRNA PSMB8-AS1 contributes to pancreatic cancer progression via modulating miR-382-3p/STAT1/PD-L1 axis. Co-author DOI 10.1186/s13046-020-01687-8↗
  30. TRIM37 Mediates Chemoresistance and Maintenance of Stemness in Pancreatic Cancer Cells via Ubiquitination of PTEN and Activation of the AKT-GSK-3β-β-Catenin Si… First author DOI 10.3389/fonc.2020.554787↗
  31. Nanomaterials: Applications in the diagnosis and treatment of pancreatic cancer. First author DOI 10.4292/wjgpt.v11.i1.1↗
  32. MiR-137 promotes anoikis through modulating the AKT signaling pathways in Pancreatic Cancer. First author DOI 10.7150/jca.44037↗
  33. LAMB3 mediates apoptotic, proliferative, invasive, and metastatic behaviors in pancreatic cancer by regulating the PI3K/Akt signaling pathway. Co-author DOI 10.1038/s41419-019-1320-z↗
  34. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. Co-author DOI 10.1186/s13046-019-1105-3↗
  35. Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway. First author DOI 10.1186/s13046-019-1388-4↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shiyu Chen · 11 shared papers, 2019–2026 · strength 1.95
  2. Dijie Zheng · 8 shared papers, 2022–2025 · strength 1.80
  3. Jianxin Jiang · 10 shared papers, 2019–2022 · strength 1.49
  4. Zhirui Zeng · 8 shared papers, 2019–2025 · strength 1.39
  5. Chao Yu · 8 shared papers, 2019–2025 · strength 1.38
  6. Kun Cai · 7 shared papers, 2022–2026 · strength 1.37
  7. Changhao Wu · 5 shared papers, 2023–2025 · strength 1.30
  8. Shan Lei · 7 shared papers, 2019–2022 · strength 1.10
  9. Wenpeng Cao · 5 shared papers, 2021–2022 · strength 0.82
  10. Jian Xu · 5 shared papers, 2021–2022 · strength 0.77
  11. Cheng-Yi Sun · 4 shared papers, 2022–2023 · strength 0.69
  12. Xueyi Jiang · 4 shared papers, 2021–2022 · strength 0.59
  13. Xinyuan Liu · 4 shared papers, 2021–2022 · strength 0.59
  14. Chengyi Sun · 5 shared papers, 2019–2020 · strength 0.56
  15. Futang Li · 2 shared papers, 2025 · strength 0.54
  16. Xinghao Sun · 2 shared papers, 2025 · strength 0.49
  17. Hao Hua · 2 shared papers, 2023–2025 · strength 0.47
  18. Chao Yu · 2 shared papers, 2022–2025 · strength 0.46
  19. Yaozhen Pan · 3 shared papers, 2019–2023 · strength 0.44
  20. Chao Yu · 2 shared papers, 2022–2025 · strength 0.43
  21. Yankun Chen · 3 shared papers, 2021 · strength 0.42
  22. Lin Li · 2 shared papers, 2022 · strength 0.36
  23. Jie Wang · 2 shared papers, 2021–2022 · strength 0.35
  24. Songbai Liu · 2 shared papers, 2023 · strength 0.34
  25. Xiaobin Fei · 2 shared papers, 2023 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.